Using modified immune cells and pembrolizumab to treat advanced lung cancer
Intratumoral Administration of CCL21-gene Modified Dendritic Cell With Intravenous Pembrolizumab for Advanced NSCLC
This study is looking at a new way to help people with advanced non-small cell lung cancer by using specially modified immune cells and a medication called pembrolizumab to boost the body's ability to fight the cancer.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Los Angeles NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project ID | NIH-10857290 on NIH RePORTER |
What this research studies
This research investigates the use of genetically modified dendritic cells, which are a type of immune cell, administered directly into tumors, combined with the drug pembrolizumab, to treat patients with advanced non-small cell lung cancer (NSCLC). The approach aims to enhance the body's immune response against cancer cells by utilizing these modified cells to better present tumor antigens. Patients will be monitored for their response to this treatment, which may involve a phase I clinical trial to assess safety and effectiveness. The research is being conducted at UCLA, where the principal investigator has extensive experience in lung cancer immunotherapy.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with advanced non-small cell lung cancer who have not responded adequately to existing therapies.
Not a fit: Patients with early-stage lung cancer or those who have not been diagnosed with lung cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new and more effective treatment option for patients with advanced lung cancer who currently have limited options.
How similar studies have performed: Previous research has shown promising results with similar immunotherapy approaches, indicating potential for success in this novel application.
Where this research is happening
Los Angeles, United States
- University of California Los Angeles — Los Angeles, United States (Active)
Researchers
- Principal investigator: Lisberg, Aaron Elliott — University of California Los Angeles
- Study coordinator: Lisberg, Aaron Elliott
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.